Prehosp Emerg Care. 2020 Jul-Aug;24(4):505-514. doi: 10.1080/10903127.2019.1679303. Epub 2019 Nov 11.
Importance: Intravenous alteplase is an effective treatment for acute ischemic stroke and is significantly underutilized. It is known that stroke centers with accreditation are more likely to provide intravenous alteplase treatment, and therefore, policies that increase the number of certified stroke centers and the number of acute ischemic stroke patients routed to these centers may be beneficial. To determine whether increasing access to primary stroke centers (regionalization) led to an increase in intravenous alteplase use in acute ischemic stroke patients. An observational, longitudinal study to examine treatment trends with log-link binomial regression modeling to compare pre-post policy implementation changes in the proportions of patients treated with intravenous alteplase in two counties. Two urban counties, Santa Clara and San Mateo, in the western region of US that regionalized acute stroke care between 2005 and 2010. Patients with primary or secondary diagnosis of stroke were identified from the statewide patient discharge database by International Classification of Diseases (ICD-9) codes. We linked ambulance and hospital data to create complete patient care records. Stroke treatment, defined as a documented primary procedure code for intravenous alteplase administration (ICD-9: 99.10). In Santa Clara County, intravenous alteplase was administered to 35 patients (1.7%) in the pre-regionalization period and 240 patients (2.1%) in the post-regionalization period. In San Mateo County, intravenous alteplase was administered to 29 patients (1.3%) in the pre-policy period and 135 patients (3.2%) in the post-policy period. After regionalization of stroke care, intravenous alteplase increased two-fold in San Mateo County [adjusted RR 2.20, = 0.003, 95% CI (1.31, 3.69)] but did not show any statistically significant change in Santa Clara County [adjusted RR 1.10, = 0.55, 95% CI (0.80, 1.51)]. In the post-regionalization phase, when compared with Santa Clara County, we found that San Mateo County had greater change in paramedic stroke detection, higher number of transports to primary stroke centers and more frequent use of intravenous alteplase at stroke centers. Our findings suggest that greater post-regionalization improvements in San Mateo County contributed to significantly better county-level thrombolysis use than Santa Clara County.
静脉注射阿替普酶是急性缺血性脑卒中的有效治疗方法,但使用率明显偏低。已知获得认证的卒中中心更有可能提供静脉注射阿替普酶治疗,因此,增加认证卒中中心的数量和将急性缺血性脑卒中患者转至这些中心的数量的政策可能是有益的。目的:确定增加初级卒中中心的可及性(区域化)是否会导致急性缺血性脑卒中患者接受静脉注射阿替普酶治疗的比例增加。这是一项观察性、纵向研究,通过对数链接二项式回归模型来检验治疗趋势,以比较两个县在实施政策前后静脉注射阿替普酶治疗患者比例的变化。两个城市县,即美国西部的圣克拉拉县和圣马特奥县,在 2005 年至 2010 年间实现了急性卒中治疗的区域化。通过国际疾病分类(ICD-9)代码,从全州患者出院数据库中确定原发性或继发性卒中诊断的患者。我们将救护车和医院数据链接起来,以创建完整的患者护理记录。卒中治疗,定义为记录的初级程序代码,用于静脉注射阿替普酶给药(ICD-9:99.10)。在圣克拉拉县,在区域化前阶段,有 35 名患者(1.7%)接受了静脉注射阿替普酶治疗,而在区域化后阶段,有 240 名患者(2.1%)接受了治疗。在圣马特奥县,在政策前阶段,有 29 名患者(1.3%)接受了静脉注射阿替普酶治疗,而在政策后阶段,有 135 名患者(3.2%)接受了治疗。卒中治疗区域化后,圣马特奥县的静脉注射阿替普酶治疗增加了两倍[调整后的 RR 2.20, = 0.003,95%CI(1.31,3.69)],但在圣克拉拉县没有显示出任何统计学上的显著变化[调整后的 RR 1.10, = 0.55,95%CI(0.80,1.51)]。在区域化后阶段,与圣克拉拉县相比,我们发现圣马特奥县在护理人员卒中检测方面的改善更大,向初级卒中中心转运的患者数量更多,卒中中心更频繁地使用静脉注射阿替普酶。我们的研究结果表明,圣马特奥县在区域化后取得了更大的改善,导致其县一级的溶栓使用率明显优于圣克拉拉县。